Diagnostic criteria and classification of mastocytosis in 2014

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 207-218

  Akin, Cem ^a   Valent, Peter ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C kit; Classification; Diagnosis; Mastocytosis; Tryptase; World Health Organization

Indexed keywords

STEM CELL FACTOR RECEPTOR; TRYPTASE; BIOLOGICAL MARKER; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; GAIN OF FUNCTION MUTATION; HUMAN; IMMUNOPATHOGENESIS; MACULOPAPULAR RASH; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; RESEARCH DIAGNOSTIC CRITERIA; REVIEW; SKIN BIOPSY; SOMATIC MUTATION; SYSTEMIC MASTOCYTOSIS; TREATMENT PLANNING; URTICARIA PIGMENTOSA; WORLD HEALTH ORGANIZATION; ADULT; AGE; BLOOD; BONE MARROW; CHILD; CLASSIFICATION; GASTROINTESTINAL TRACT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PRACTICE GUIDELINE; SKIN;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BONE MARROW; CHILD; GASTROINTESTINAL TRACT; GENE EXPRESSION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MASTOCYTOSIS; MUTATION; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS C-KIT; SKIN; TRYPTASES;

EID: 84898677462     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.02.003     Document Type: Review

References (68)

1. Akin C., Metcalfe D.D. Systemic mastocytosis. Annu Rev Med 2004, 55:419.
2. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946.
3. Valent P., Akin C., Sperr W.R., et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46:35.
4. Arock M., Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010, 3:497.
5. Fried A.J., Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013, 13:693.
6. Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12:259.
7. Carter M.C., Metcalfe D.D. Paediatric mastocytosis. Arch Dis Child 2002, 86:315.
8. Pardanani A., Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010, 17:125.
9. Pardanani A., Lim K.H., Lasho T.L., et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010, 115:150.
10. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769.
11. Escribano L., Alvarez-Twose I., Sanchez-Munoz L., et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. JAllergy Clin Immunol 2009, 124:514.
12. Valent P., Akin C., Sperr W.R., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003, 27:635.
13. Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010, 116:5812.
14. Georgin-Lavialle S., Lhermitte L., Dubreuil P., et al. Mast cell leukemia. Blood 2013, 121:1285.
15. Valent P, Sotlar K, Sperr WR, etal. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol, in press.
16. Ryan R.J., Akin C., Castells M., et al. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2013, 26:533.
17. Hahn H.P., Hornick J.L. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007, 31:1669.
18. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603.
19. Valent P., Horny H.P., Li C.Y., et al. Mastocytosis. World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues 2001, 291. IARC Press, Lyon (France). E.S. Jaffe, N.L. Harris, H. Stein (Eds.).
20. Horny H.P., Metcalfe D.D., Bennett J.M., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, vol. 2:54. IARC Press, Lyon (France). 4th edition.
21. Akin C., Jaffe E.S., Raffeld M., et al. An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells. Am J Clin Pathol 2002, 118:242.
22. Horny H.P., Lange K., Sotlar K., et al. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. JClin Pathol 2003, 56:575.
23. Sperr W.R., Escribano L., Jordan J.H., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001, 25:529.
24. Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001, 25:543.
25. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731.
26. Escribano L., Diaz-Agustin B., Lopez A., et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004, 58:1.
27. Morgado J.M., Sanchez-Munoz L., Teodosio C.G., et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012, 25:516.
28. Pardanani A., Kimlinger T.K., Reeder T.L., et al. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003, 120:691.
29. Sotlar K., Horny H.P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319.
30. Akin C., Valent P., Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006, 6:282.
31. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560.
32. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312.
33. Kristensen T., Vestergaard H., Bindslev-Jensen C., et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014 Jan 20, [Epub ahead of print]. 10.1002/ajh.23672.
34. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. JMol Diagn 2006, 8:412.
35. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012, 26:951.
36. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. JInvest Dermatol 2010, 130:804.
37. Akin C., Kirshenbaum A.S., Semere T., et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28:140.
38. Akin C. Multilineage hematopoietic involvement in systemic mastocytosis. Leuk Res 2003, 27:877.
39. Akin C., Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. JAllergy Clin Immunol 2004, 114:13.
40. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99:1741.
41. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686.
42. Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001, 25:553.
43. Schwartz L.B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006, 26:451.
44. Schwartz L.B., Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:641.
45. Schwartz L.B., Metcalfe D.D., Miller J.S., et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. NEngl J Med 1987, 316:1622.
46. Schwartz L.B., Sakai K., Bradford T.R., et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. JClin Invest 1995, 96:2702.
47. Sperr W.R., El-Samahi A., Kundi M., et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009, 39:914.
48. Akin C., Scott L.M., Kocabas C.N., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331.
49. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. JAllergy Clin Immunol 2010, 126:1099.
50. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435.
51. Akin C., Fumo G., Yavuz A.S., et al. Anovel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222.
52. Morgado J.M., Perbellini O., Johnson R.C., et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013, 63:780.
53. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. JAllergy Clin Immunol 2010, 125:719.
54. Alvarez-Twose I., Gonzalez P., Morgado J.M., et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. JClin Oncol 2012, 30:e126.
55. Akin C. Anaphylaxis and mast cell disease: what is the risk?. Curr Allergy Asthma Rep 2010, 10:34.
56. Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63:226.
57. Gulen T., Hagglund H., Dahlen B., et al. High prevalence of anaphylaxis in patients with systemic mastocytosis-a single-centre experience. Clin Exp Allergy 2014, 44:121.
58. van der Veer E., van der Goot W., de Monchy J.G., et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012, 67:431.
59. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123:680.
60. Alvarez-Twose I., Bonadonna P., Matito A., et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. JAllergy Clin Immunol 2013, 131:614.
61. Akin C., Scott L.M., Metcalfe D.D. Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case?. Leuk Res 2001, 25:635.
62. Jordan J.H., Fritsche-Polanz R., Sperr W.R., et al. Acase of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk Res 2001, 25:627.
63. Valent P., Akin C., Sperr W.R., et al. Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol 2002, 127:137.
64. Sperr W.R., Horny H.P., Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002, 127:140.
65. Kluin-Nelemans H.C., Ferenc V., van Doormaal J.J., et al. Lenalidomide therapy in systemic mastocytosis. Leuk Res 2009, 33:e19.
66. Du S., Rashidi H.H., Le D.T., et al. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol 2010, 3:448.
67. Sperr W.R., Jordan J.H., Fiegl M., et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002, 128:136.
68. Castells M.C. Extracutaneous mastocytoma. JAllergy Clin Immunol 2006, 117:1513.